Regeneron Pharmaceuticals' Non Operating Income rose 91481.48% to $176.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.7 billion, marking a year-over-year increase of 10482.92%. This contributed to the annual value of $1.7 billion for FY2025, which is 10092.37% up from last year.
As of Q4 2025, Regeneron Pharmaceuticals' Non Operating Income stood at $176.0 million, which was up 91481.48% from $755.8 million recorded in Q3 2025.
Regeneron Pharmaceuticals' Non Operating Income's 5-year high stood at $755.8 million during Q3 2025, with a 5-year trough of -$197.4 million in Q1 2022.
Its 5-year average for Non Operating Income is $167.4 million, with a median of $165.4 million in 2021.
Per our database at Business Quant, Regeneron Pharmaceuticals' Non Operating Income tumbled by 26878.45% in 2021 and then skyrocketed by 175965.91% in 2024.
Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Non Operating Income stood at -$122.2 million in 2021, then surged by 294.19% to $237.3 million in 2022, then decreased by 18.67% to $193.0 million in 2023, then crashed by 111.19% to -$21.6 million in 2024, then skyrocketed by 914.81% to $176.0 million in 2025.
Its Non Operating Income was $176.0 million in Q4 2025, compared to $755.8 million in Q3 2025 and $442.8 million in Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value